CFTR and cystic fibrosis: Our analysis has brought valuable insights on the regulatory decision-making process of FDA and EMA on CFTR modulators for the treatment of CF, emphasizing the role of regulators in fostering the development and approval of these medicines and the streamlined access to a growing number of patients.